Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Public biotech 2013—the numbers

Nature Biotechnology volume 32, pages 626–632 (2014)Cite this article

Subjects

An Erratum to this article was published on 07 August 2015

An Erratum to this article was published on 07 November 2014

This article has been updated

2013 was truly a year to remember for the public biotech sector, with the largest wave of IPOs since the 2000–2001 bubble.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: NASDAQ biotech index over time.
Figure 2
Figure 3: Global biotech industry financing.
Figure 4: Public biotech barometers.

Change history

  • 03 September 2014

    In the version of this article initially published, in Table 8, Enbrel (etanercept) was left off the table. It should have been in the number 2 spot in the table with 2013 revenue at $8,739 million. In addition, the units of the last column, which are in $ millions, were omitted in the title. The errors have been corrected in the HTML and PDF versions of the article.

  • 25 June 2015

    In the version of the article initially published, some companies that went public in 2013 were missing from the table of 2013 IPOs (Table 4). Thirteen companies have been added to the table, including Celyad (formerly Cardio3 Biosciences), Erytech, Immunicum, Innate Immune Therapeutics, Kadimastem, Karyopharm Therapeutics, Kindred, Macrogenics, Oncolys Biopharma, Reprocell, Tetralogic, Veracyte and Xencor; in the figure of global IPOs (Fig. 2), the number of IPOs in 2013 and the average dollar amount raised have been corrected to reflect the additional companies.

Author information

Authors and Affiliations

  1. Stacy Lawrence is a freelance writer based in San Francisco.,

    Stacy Lawrence

  2. Riku Lahteenmaki is a freelance writer working in Turku, Finland.,

    Riku Lahteenmaki

Authors
  1. Stacy Lawrence
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Riku Lahteenmaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lawrence, S., Lahteenmaki, R. Public biotech 2013—the numbers. Nat Biotechnol 32, 626–632 (2014). https://doi.org/10.1038/nbt.2949

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2949

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research